Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine plus erlotinib in stage IV non-squamous NSCLC
2011-004903-20Phase 2Active
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine and erlotinib in non-small cell lung cancer (NSCLC). Primary endpoint: Metabolic tumor activity change by 18F-FDG PET at 1 week. Started Feb 2012; status: active.
02
Drugs
hydroxychloroquineerlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-004903-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004903-20.